FTC Claims Pharmacy Benefit Managers Inflate Prices, Harm Smaller Drugstores: Report

In a dissenting opinion, FTC Commissioner Melissa Holyoak said the report failed to provide empirical evidence to support the conclusions.
FTC Claims Pharmacy Benefit Managers Inflate Prices, Harm Smaller Drugstores: Report
Lina Khan, then-nominee for FTC commissioner, speaks during a hearing on Capitol Hill, on April 21, 2021. Graeme Jennings/AP Photo
|Updated:
0:00

Dominant pharmacy benefit managers (PBMs) are hiking the cost of drugs and squeezing independent pharmacies that many Americans depend on for essential care, according to a Federal Trade Commission (FTC) interim report released on July 9.

The report examined the roles PBMs play in the pharmaceutical supply chain, highlighting their impact on drug prices, access to medications, and the viability of independent pharmacies.
Chase Smith
Chase Smith
Author
Chase is an award-winning journalist. He covers national politics for The Epoch Times. For news tips, send Chase an email at [email protected] or connect with him on X.
twitter